Article
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
Cancer discovery - 4 Aug 2023
Stossel Chani, Raitses-Gurevich Maria, Atias Dikla, Beller Tamar, Glick Gorman Yulia, Halperin Sharon, Peer Eyal, Denroche Robert E, Zhang Amy, Notta Faiyaz, Wilson Julie M, O'Kane Grainne M, Haimov Talmoud Elina, Amison Nora, Schvimer Michael, Salpeter Seth J, Bar Vered, Zundelevich Adi, Tirosh Itay, Tal Rotem, Dinstag Gal, Kinar Yaron, Eliezer Yonatan, Ben-David Uri, Gavert Nancy S, Straussman Ravid, Gallinger Steven J, Berger Raanan, Golan Talia
Abstract excerpt
Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS <36 months), and (iii) long-term responders...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.